Clinical Trials match your criteria
-
Cabozantinib With Nivolumab and Ipilimumab in Rare GU Tumors
PHASE II STUDY OF CABOZANTINIB IN COMINATION WITH NIVOLUMAB AND IPILIMUMAB IN RARE GENITOURINARY TUMORS
-
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
-
The Rare Brain Tumour Consortium Registry and Biobank
The Rare Brain Tumour Consortium Registry and Biobank
-
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (P3BEP)
AGCT1532 - Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
-
WARRIOR
Women’s Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR)
-
Phase 2 study of Autologous TIL's for patients with solid tumors
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors
-
Pediatric Hepatic Malignancy International Therapeutic Trial
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
-
Head Start 4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors
Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation with Either Single Cycle (Low Risk Patients) or Randomization (High Risk Patients) to Either Single-Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue
-
Web-Based Physical Activity Intervention to Improve Health in Children with Leukemia
A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia
-
Neoadjuvant therapy for abnormal HER2- Signaling
An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected with a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1)
